2. Pinduli I., Spivacow R., del Valle E., Vidal S., Negri A.L., Previgliano H., Farias Edos R., Andrade J.H., Negri G.M., Boffi-Boggero H.J. Prevalence of urolithiasis in the autonomous city of Buenos Aires, Argentina. Urol Res. 2006; 34(1):8–11. Doi:10.1007/s00240-005-0003-7.

3. Medina-Escobedo M., Zaidi M., Real-de Leon E., Orozco-Rivadeneyra S. Urolithiasis prevalence and risk factors in Yucatan, Mexico. Salud Publica de Mexico. 2002;44(6):541–545.

4. Rompsaithong U., Jongjitaree K., Korprsphong P., Woranisarakul V., Taweemonkongsap T., Nuaiyong C., Chotikawanich E. Characterization of renal stone composition by using fast kilovoltage switching dual-energy computed tomography compared to laboratory stone analysis: a pilot study. Abdom.Radiol (NY). 2019;44(3):1027–1032. Doi: 10.1007/s00261-018-1787-6.

5. Pearle M.S., Calhoun E.A., Curhan G.C. Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol. 2005;173:848-57.

6. Daudon M., Doré J.-C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol. Res. 2004;32:241–247.

7. Resnick M., Pridgen D.B., Goodman H.O. Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med. 1968;278(24):1313–1318. Doi:10.1056/NEJM196806132782403;

8. Coe F.L., Parks J.H., Moore E.S. Familial idiopathic hypercalciuria. N Engl J Med. 1979;300(7):337–340. Doi: 10.1056/NEJM197902153000703.

9. Curhan G.C., Willett W.C., Rimm E.B., Stampfer M.J. Family history and risk of kidney stones. J Am Soc Nephrol JASN 1997;8(10):1568–1573.

10. McGeown M.G. Heredity in renal stone disease. Clin Sci. 1960;19:465–471.

11. Stechman M.J., Loh N.Y., Thakker R.V. Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann N.Y. Acad Sci. 2007;1116:461–484. Doi:10.1196/annals.1402.030.

12. Goldfarb D.S., Fischer M.E., Keich Y., Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int. 2005;67(3):1053–1061. Doi: 10.1111/j.1523-1755.2005.00170.x.

13. Hunter D.J., Lange M., Snieder H., MacGregor A.J., Swaminathan R., Thakker R.V., Spector T.D. Genetic contribution to renal function and electrolyte balance: a twin study. Clin Sci (Lond). 2002;103(3):259–265. Doi: 10.1042/cs1030259.

14. Monga M., Macias B., Groppo E., Hargens A. Genetic heritability of urinary stone risk in identical twins. J Urol. 2006;175(6):2125–2128. Doi: 10.1016/S0022-5347(06)00272-2.

15. David S.. Goldfarb, Ally R. Avery, Lada Beara-Lasic, Glen E. Duncan and Jack Goldberg. A Twin Study of Genetic Influences on Nephrolithiasis in Women and Men. Kidney International Reports. 2019;4:535–540.

16. Esposito T., Rendina D., Aloia A., Formicola D., Magliocca S., De Filippo G., Muscariello R., Mossetti G., Gianfrancesco F., Strazzullo P. The melatonin receptor 1 A (MTNR1A) gene is associated with recurrent and idiopathic calcium nephrolithiasis. Nephrol Dial Transp. 2012;27(1):210–218. Doi: 10.1093/ndt/gfr216.

17. Hou J. The role of claudin in hypercalciuric nephrolithiasis. Curr Urol Rep. 2013;14(1):5–12. Doi 10.1007/s11934-012-0289-2.

18. Walker V., Stansbridge E.M., Griffin D.G. Demography and biochemistry of 2800 patients from a renal stones clinic. Ann Clin Biochem. 2013;50(Pt 2):127–139. Doi 10.1258/ acb.2012.012122.

19. Zeng Q., He Y. Age-specific prevalence of kidney stones in Chinese urban inhabitants. Urolithiasis. 2013;41(1):91–93. Doi: 10.1007/s00240-012-0520-0.

20. Scales C.D., Jr., Smith A.C., Hanley J.M., Saigal C.S. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160–165.

21. Lieske J.C., Pena de la Vega L.S., Slezak J.M., Bergstralh E.J., Leibson C.L.,Ho K.L., Gettman M.T. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760–764. Doi: 10.1038/sj.ki.5000150.

22. Antonelli J.A., Maalouf N.M., Pearle M.S., Lotan Y. Use of the national health and nutrition examination survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol. 2014;66(4):724–729.

23. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455–462. Doi: 10.1001/jama.293.4.455.

24. Curhan G.C., Willett W.C., Rimm E.B., Speizer F.E., Stampfer M.J. Body size and risk of kidney stones. J Am Soc Nephrol JASN. 1998;9(9):1645–1652.

25. Wong Y., Cook P., Roderick P., Somani Bh.K. Metabolic Syndrome and Kidney Stone Disease: A Systematic Review of Literature; https://doi.org/10.1089/end.2015.0567

26. Ekeruo W.O., Tan Y.H., Young M.D., Dahm P., Maloney M.E., Mathias B.J.,Albala D.M., Preminger G.M. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol. 2004;172(1):159–163. doi:10.1097/01.ju.0000128574.50588.97.

27. Maalouf N.M., Sakhaee K., Parks J.H., Coe F.L., Adams-Huet B., Pak C.Y. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422–1425. Doi: 10.1111/j.1523-1755.2004.00522.x.

28. Maalouf N.M. Metabolic syndrome and the genesis of uric acid stones. J Renal Nutr. 2011;21(1):128–131. Doi:10.1053/j.jrn.2010.10.015.

29. DeFronzo R.A., Cooke C.R., Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;4:845–855.

30. Bobulescu I.A., Dubree M., Zhang J., McLeroy P., Moe O.W. Effect of renal lipid accumulation on proximal tubule Na+/H + exchange and ammonium secretion. Am J Physiol Renal Physiol. 2008;294 (6):F1315–1322. Doi: 10.1152/ajprenal.00550.2007.

31. Bobulescu I.A., Dubree M., Zhang J., McLeroy P., Moe O.W. Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+exchange and urinary acidification. Am J Physiol Renal Physiol. 2009;297(5):F1419–1426. Doi: 10.1152/ajprenal.00177.2009.

32. Daudon M., Traxer O., Conort P., Lacour B., Jungers P. Type 2 diabetes increases the risk for uric acid stones. JAm Soc Nephrol JASN. 2006;17(7):2026–2033. Doi: 10.1681/ASN.2006030262.

33. Case C.C., Jones P.H., Nelson K., O’Brian Smith E., Ballantyne C.M. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002;4(6):407–414.

34. Noakes M., Foster P.R., Keogh J.B., Clifton P.M. Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. J Nutr 2004;134(8):1894–1899.

35. Torris C., Molin M., Cvancarova Smastuen M. Fish consumption and its possible preventive role on the development and prevalence of metabolic syndrome - a systematic review. Diabetol Metab Syndr 2014;6(1):112. Doi: 10.1089/end.2015.0567.

36. Anderssen S.A., Carroll S., Urdal P., Holme I. Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: results from the Oslo Diet and Exercise Study. Scand J Med Sci Sports 2007;17(6):687–695.

37. Kotsiris D., Adamou K., Kallidonis P. Diet and stone formation: a brief review of the literature. Curr Opin Urol. 2018;28. Doi: 10.1097/MOU.0000000000000521.

38. Ferraro P.M., Taylor E.N., Gambaro G., Curhan G.C. Dietary and lifestyle risk factors associated with incident kidney stones in men and women. J Urol 2017;198:858–863.

39. Ticinesi A., Nouvenne A., Borghi L., Meschi T. Water and other fluids in nephrolithiasis: state of the art and future challenges. Crit Rev Food Sci Nutr 2017;57:963–974.

40. Borghi L., Meschi T., Amato .F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155:839–843.

41. Curhan G.C., Willett W.C., Rimm E.B., et al. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol. 1996;143:240–247.

42. Shuster J., Jenkins A., Logan C., et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol. 1992;45:911–916.

43. Ferraro P.M., Taylor E.N., Gambaro G., Curhan G.C. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol. 2013;8:1389–1395.

44. Fox I.H., Kelley W.N. Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism 1972; 21:713–721.

45. Nguyen N.U., Dumoulin G., Henriet M.T., Regnard J. Increase in urinary calcium and oxalate after fructose infusion. Horm Metab Res. 1995;27:155–158.

46. Taylor E.N., Curhan G.C. Fructose consumption and the risk of kidney stones. Kidney Int. 2008;73:207–212.

47. García-Arroyo F.E., Tapia E., Blás-Marrón M.G., Gonzaga G., Silverio O.,Cristóbal M., Osorio H., Arellano-Buendía A.S., Zazueta C., Aparicio-Trejo O..E, et al. Vasopressin mediates the renal damage induced by limited fructose rehydration in recurrently dehydrated rats. Int J Biol Sci. 2017;13(8).

48. Knochel J.P., Dotin L.N., Hamburger R.J. Heat stress, exercise, and muscle injury: effects on urate metabolism and renal function. Ann Intern Med. 1974;81(3):321–328.

49. Roncal-Jimenez C., Garcia-Trabanino R., Barregard L., Lanaspa M.A., Wesseling C., Harra T., Aragon A., Grases F., Jarquin E.R., Gonzalez M.A.,et al. Heat stress nephropathy from exercise-induced uric acid Crystalluria: a perspective on Mesoamerican nephropathy. Am J Kidney Dis. 2016;67(1):20–30.

50. Johnson et al. BMC Nephrology. 2018;19:315 https://doi.org/10.1186/s12882-018-1105-0

51. Senthy Sellaturay, Christopher Henry Fry. The metabolic basis for urolithiasis. Surgery. 2008;26(4):136–140.

52. Worcester E.M., Coe F.L. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954–963. Doi: 10.1056/NEJMcp1001011.

53. Pearle M.S., Goldfarb D.S., Assimos D.G., Curhan G., Denu-Ciocca C.J., Matlaga B.R., Monga M., Penniston K.L., Preminger G.M., Turk T.M., White J.R. American Urological A. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316–324. Doi: 10.1016/j.juro.2014.05.006.

54. Johri N., Cooper B., Robertson W., Choong S., Rickards D., Unwin R. An update and practical guide to renal stone management. Nephron Clin Pract. 2010;116(3):c159–171. Doi: 10.1159/000317196.

55. Nouvenne A., Meschi T., Guerra A., Allegri F., Prati B., Borghi L. Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab. 2008;5(2):135–141.

56. Sakhaee K., Maalouf N.M., Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.J Clin Endocrinol Metab. 2012;97(6):1847–1860. Doi:10.1210/jc.2011–3492.

57. Nouvenne A., Meschi T., Guerra A., Allegri F., Prati B., Borghi L. Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab. 2008;5(2):135–141.

58. Eisner B.H., Thavaseelan S., Sheth S., Haleblian G., Pareek G. Relationship between serum vitamin D and 24-hour urine calcium in patients with nephrolithiasis. Urology. 2012;80(5):1007–1010. Doi: 10.1016/j.urology.2012.04.041.

59. Hall P.M. Nephrolithiasis: treatment, causes, and prevention. Clevel Clin J Med. 2009;76(10):583–591. Doi: 10.3949/ccjm.76a.09043.

60. Sayer J.M.S., homas D. The medical management of urolithiasis. Br J Med Surg Urol. 2010;3(3):87–95.

61. Assimos D.G. Evaluation of the stone former. In: Denstedt J, Khoury S (eds) Stone disease. Health Publications, Paris, 2008.33–36.

62. Goldfarb D.T.A., Curhan G. Epidemiology of stone disease.In: Denstedt J, Khoury S (eds) Stone disease. Health Publications, Paris, 2008,11–19.

63. Dussol B., Iovanna C., Rotily M., Morange S., Leonetti F., Dupuy P., Vazi A., Saveanu A., Loundou A., Berland Y. A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis. Nephron Clin Pract. 2008;110(3):185–194. Doi: 10.1159/000167271

64. Fakhoury M.Q., Gordon B., Shorter B., Renson A., Borofsky M.S., Cohn M.R.,Cabezon E., Wysock J.S., Bjurlin M.A. Perceptions of dietary factors promoting and preventing nephrolithiasis: a cross-sectional survey. World J Urol. 2018. Doi: 10.1007/s00345-018-2562-6.

65. Nutritional Management of kidney stones (nephrolitiasis) H. Han, A.M. Segal, J.L. Seifter, J.T. Dwyer. Clin. Nutr. Res. 2015;4:137–152. Doi.org/10.7762/cnr.2015.4.3.137.

66. Cappuccio F.P., Siani A., Barba G., Mellone M.C., Russo L., Farinaro E., Trevisan M., Mancini M., Strazzullo P. A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens. 1999;17(7):1017–1022.

67. Borghi L., Meschi T., Guerra A., Briganti A., Schianchi T., Allegri F., Novarini A. Essential arterial hypertension and stone disease. Kidney Int. 1999;55(6):2397–2406. Doi: 10.1046/j.1523-1755.1999.00483.

68. Gillen D.L, Coe F.L., Worcester E.M. Nephrolithiasis and increased blood pressure among females with high body mass index. Am J Kidney Dis. 2005;46(2):263–269. Doi: 10.1053/j. ajkd.2005.04.030.

69. Taylor E.N., Stampfer M.J., Mount D.B., Curhan G..C. DASH-style diet and 24-hour urine composition. Clin J Am Soc Nephrol CJASN. 2010;5(12):2315–2322. Doi: 10.2215/CJN.04420510.

70. Kramer H.M., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40(1):37–42. Doi: 10.1053/ajkd.2002.33911.

71. Dominguez-Gutierrez P.R., Kusmartsev S., Canales B.K., Khan S.R. Calcium oxalate differentiates human monocytes into inflammatory M1 macrophages. Front Immunol 2018;9:1863.

72. Patel M., Yarlagadda V., Adedoyin O., et al. Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol. 2018;15:207–215.

73. Anders H.J., Suarez-Alvarez B., Grigorescu M., et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosisrelated chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int. 2018;93:656–669.

74. Dominguez-Gutierrez P.R., Kwenda E.P., Khan S.R., Canales B.K. Immunotherapy for stone disease. Curr Opin Urol. 2020 Jan 6. Doi: 10.1097/MOU.0000000000000729.